Rabies Immunoglobulin Market Share, Sales Channels and Overview Till 2028

Rabies is a zoonotic viral disease caused due to animal bites. The disease is mainly transmitted from domestic and wild animals such as bats, foxes, cats, or dogs and infects humans upon contacting infected animal saliva. Its incubation period is of one to three months. Several symptoms are shown in individuals suffering from rabies, such as fever and pain or burning sensation (paraesthesia) at the wound site. One of the approved and effective methods against rabies is rabies immunoglobulin, i.e., a medication made up of antibodies against the rabies virus to prevent rabies.

Download PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00023944/?utm_source=OpenPR&utm_medium=10357

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the rabies immunoglobulin market in these regions.

Leading Companies:

1. Grifols USA
2. CSL Behring
3. Sichuan Yuanda Shuyang
4. Sanofi
5. Shanghai RAAS
6. KEDRAB
7. Bharat Serum
8. Kamada
9. Vins Bioproducts Limited.
10. Bio Products Laboratory Limited

IMPACT OF COVID-19 ON RABIES IMMUNOGLOBULIN MARKET

COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 pandemic had affected the growth of the market. As per the data of the CDC, 2020, several animals, including cats, dogs, and a few other types of animals, were at potential risk of acquiring the virus. Therefore, a study was conducted that showed the rapid development of a novel, highly efficient, and safe COVID-19 vaccine via a rabies virus-based vector which proved to be an efficient vaccine against several emerging infectious diseases. Hence, the market growth was surged due to these developments during the pandemic.

Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00023944/?utm_source=OpenPR&utm_medium=10357

About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.